← Eichor
Study identifier: NCT06528418 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

Condition: Lung Cancer · Lung Infection · COPD  ·  Sponsor: ChromX Health

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersYes

About this study

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases. 2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Hengrui Liang, MD  ·  +86 15625064712  ·  hengrui_liang@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06528418